Skip to main content
Log in

High-Dose N-Acetylcysteine in Patients with Exacerbations of Chronic Obstructive Pulmonary Disease

  • Original Research Article
  • Published:
Clinical Drug Investigation Aims and scope Submit manuscript

Abstract

Objective: To investigate the efficacy and tolerability of high-dose N-acetylcysteine (NAC) in the treatment of patients with exacerbations of chronic obstructive pulmonary disease (COPD).

Design and patients: Randomised, double-blind, double-dummy, placebo-controlled study in 123 patients experiencing an acute exacerbation of COPD.

Interventions: NAC 1200 mg/day, 600 mg/day or placebo administered once daily for 10 days.

Main outcome measures: The primary objective was to assess the proportion of patients with normalised C-reactive protein (CRP) levels. Also assessed were effects on interleukin (IL)-8 levels, lung function and symptoms. Results: Both NAC 600 and 1200 mg/day were associated with a significantly higher proportion of patients achieving normalised CRP levels compared with placebo (52% and 90% vs 19% of patients; p ≤ 0.01); however, NAC 1200 mg/day was superior to NAC 600 mg/day (p = 0.002). Furthermore, treatment with NAC 1200 mg/day was more efficacious than NAC 600 mg/day in reducing IL-8 levels and difficulty of expectoration, while the two active regimens had similar beneficial effects on lung function and other clinical outcomes (cough intensity and frequency, and lung auscultation). Treatments were well tolerated with one adverse event reported in NAC 1200 mg/day recipients and two reported in placebo recipients.

Conclusion: Treatment with NAC 1200 mg/day improved biological markers and clinical outcomes in patients with COPD exacerbations. It is speculated that the effect of NAC on inflammatory markers may be due to both mucolytic and antioxidant properties.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Table II

Similar content being viewed by others

References

  1. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. American Thoracic Society. Am J Respir Crit Care Med 1995; 152 (5 Pt 2): S77–121

    Google Scholar 

  2. Siafakas NM, Vermeire P, Pride NB, et al. Optimal assessment and management of chronic obstructive pulmonary disease (COPD). The European Respiratory Society Task Force. Eur Respir J 1995; 8(8): 1398–420

    Article  PubMed  CAS  Google Scholar 

  3. Weiss SJ. Tissue destruction by neutrophils. N Engl J Med 1989; 320(6): 365–76

    Article  PubMed  CAS  Google Scholar 

  4. Murphy TF, Sethi S. Bacterial infection in chronic obstructive pulmonary disease. Am Rev Respir Dis 1992; 146(4): 1067–83

    PubMed  CAS  Google Scholar 

  5. Dekhuijzen PN, Aben KK, Dekker I, et al. Increased exhalation of hydrogen peroxide in patients with stable and unstable chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1996; 154 (3 Pt 1): 813–6

    PubMed  CAS  Google Scholar 

  6. Heffner JE, Repine JE. Pulmonary strategies of antioxidant defense. Am Rev Respir Dis 1989; 140(2): 531–54

    Article  PubMed  CAS  Google Scholar 

  7. Stey C, Steurer J, Bachmann S, et al. The effect of oral N-acetylcysteine in chronic bronchitis: a quantitative systematic review. Eur Respir J 2000; 16(2): 253–62

    Article  PubMed  CAS  Google Scholar 

  8. Grandjean EM, Berthet P, Ruffmann R, et al. Efficacy of oral long-term N-acetylcysteine in chronic bronchopulmonary disease: a meta-analysis of published double-blind, placebo-controlled clinical trials. Clin Ther 2000; 22(2): 209–21

    Article  PubMed  CAS  Google Scholar 

  9. Dekhuijzen PN. Antioxidant properties of N-acetylcysteine: their relevance in relation to chronic obstructive pulmonary disease. Eur Respir J 2004; 23(4): 629–36

    Article  PubMed  CAS  Google Scholar 

  10. Kharazmi A. The anti-inflammatory properties of N-acetylcysteine. Eur Respir Rev 1992; 2(7): 32–4

    Google Scholar 

  11. Aruoma OI, Halliwell B, Hoey BM, et al. The antioxidant action of N-acetylcysteine: its reaction with hydrogen peroxide, hydroxyl radical, superoxide, and hypochlorous acid. Free Radic Biol Med 1989; 6(6): 593–7

    Article  PubMed  CAS  Google Scholar 

  12. De Benedetto F, Aceto A, Dragani B, et al. Long-term oral N-acetylcysteine reduces exhaled hydrogen peroxide in stable COPD. Pulm Pharmacol Ther 2005; 18(1): 41–7

    Article  Google Scholar 

  13. Kasielski M, Nowak D. Long-term administration of N-acetylcysteine decreases hydrogen peroxide exhalation in subjects with chronic obstructive pulmonary disease. Respir Med 2001; 95(6): 448–56

    Article  PubMed  CAS  Google Scholar 

  14. Pinkus R, Weiner LM, Daniel V. Role of oxidants and antioxidants in the induction of AP-1, NF-κB, and glutathione S-transferase gene expression. J Biol Chem 1996; 271(23): 13422–9

    Article  PubMed  CAS  Google Scholar 

  15. van Beurden WJ, Smeenk FW, Harff GA, et al. Markers of inflammation and oxidative stress during lower respiratory tract infections in COPD patients. Monaldi Arch Chest Dis 2003; 59(4): 273–80

    PubMed  Google Scholar 

  16. Malo O, Sauleda J, Busquets X, et al. Systemic inflammation during exacerbations of chronic obstructive pulmonary disease. Arch Bronconeumol 2002; 38(4): 172–6

    PubMed  CAS  Google Scholar 

  17. Aaron SD, Angel JB, Lunau M, et al. Granulocyte inflammatory markers and airway infection during acute exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 163(2): 349–55

    PubMed  CAS  Google Scholar 

  18. Vestbo J, Prescott E, Lange P. Association of chronic mucous hypersecretion with FEV1 decline and chronic obstructive pulmonary disease morbidity. Copenhagen City Heart Study Group. Am J Respir Crit Care Med 1996; 153(5): 1530–5

    PubMed  CAS  Google Scholar 

  19. Allegra L, Blasi F, Capone P, et al. Proprietà mucoattive ed antiossidanti della NAC (N-acetilcisteina) ad alte dosi. G Ital Mal Torace 2002; 56(3): 193–202

    Google Scholar 

Download references

Acknowledgements

The cooperation of Dr A Gasparetto is gratefully acknowledged. The authors have not provided any information on funding or on any potential conflicts of interest that they may have that are directly relevant to the contents of this manuscript.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to R. Zuin.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Zuin, R., Palamidese, A., Negrin, R. et al. High-Dose N-Acetylcysteine in Patients with Exacerbations of Chronic Obstructive Pulmonary Disease. Clin. Drug Investig. 25, 401–408 (2005). https://doi.org/10.2165/00044011-200525060-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00044011-200525060-00005

Keywords

Navigation